This year’s World Hepatitis Day "Chao Wen Tian Xia" reported a series of astonishing figures: Hepatitis B and C affect 325 million people worldwide. At present, there are about 70 million hepatitis B virus carriers in my country, and about 20-30 million people need treatment. , And only 18% can be diagnosed. These data show that the prevention and treatment of hepatitis B is still a big challenge.
Early screening and diagnosis is the key to effective control of hepatitis B infectious diseases. HBsAg is the first serum marker to appear after hepatitis B virus infection. It has high predictive value and is currently the most clinically used serum marker. It is also recognized by the WHO for judging HBV infection. Key indicators. High sensitivity, high specificity, and quantitative detection are the three major trends in HBsAg detection. Acridine ester chemiluminescence immunoassay has the characteristics of simple luminescence system, no catalyst, high sensitivity and few interference factors. It is widely used in the diagnosis of tumor markers, infectious diseases, especially viral hepatitis.
Some researchers have established a method for detecting HBsAg content in human serum/plasma based on the principle of chemiluminescence immunoquantitative analysis, using acridine ester labeling analysis technology and double-antibody sandwich method. This method uses a two-step method (washing twice). First, the sample is reacted with the biotinylated hepatitis B virus surface antibody (Anti-HBs). If the sample contains HBsAg, it will form an antigen-antibody complex , Adding streptavidin-coated particles, the complex forms a solid phase under the interaction of biotin and streptavidin. Then the reaction solution is placed in a magnetic field, the magnetic particles under test will be adsorbed, and the unbound substances will be washed and removed by washing. Then add the acridine ester labeled Anti. HBs reacts with the HBsAg complex on the magnetic particles, and the unbound substance is washed and removed by washing. Finally, a chemiluminescence buffer is injected to detect the intensity of the chemiluminescence photons, and the light intensity generated is proportional to the concentration of HBsAg in the sample.
The chemiluminescence quantitative detection kit based on the hepatitis B surface antigen acridinium ester chemiluminescence quantitative immunoassay method can be effectively used in the clinical diagnosis of hepatitis B and the dynamic monitoring of the disease. It has high sensitivity, good specificity, accurate quantification, and all performance indicators. It has the advantages of meeting clinical needs, and the price is relatively high in acceptability of imported reagents. It has great potential for large-scale clinical application and is of great significance for the prevention and treatment of hepatitis B.
Desheng is a professional company engaged in the research, development, production, sales and technical services of biochemical reagents, polymer materials and equipment, import and export of goods, technology import and export, and agent import and export. Although there is no ability to produce chemiluminescence quantitative detection kits, it can provide 6 kinds of acridinium ester products (acridinium ester DMAE-NHS, acridinium ester NSP-DMAE-NHS, acridinium salt NSP-SA, acridinium salt NSP-SA-NHS, acridine hydrazide NSP-SA-ADH, acridinium ester ME-DMAE-NHS), as well as the luminescent substrates luminol and isoluminol.
Contact Person: Miss. Ankiwang